James B. Breitmeyer
Net Worth
Last updated:
What is James B. Breitmeyer net worth?
The estimated net worth of Dr. James B. Breitmeyer is at least $2,345,400 as of 14 Apr 2023. He has received compensation worth at least $2,345,400 in Oncternal Therapeutics, Inc..
What is the salary of James B. Breitmeyer?
Dr. James B. Breitmeyer salary is $781,800 per year as Pres, Chief Executive Officer & Director in Oncternal Therapeutics, Inc..
How old is James B. Breitmeyer?
Dr. James B. Breitmeyer is 71 years old, born in 1954.
What stocks does James B. Breitmeyer currently own?
As insider, Dr. James B. Breitmeyer owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Oncternal Therapeutics, Inc. (ONCT) | Pres, Chief Executive Officer & Director | 194,294 | $0 | $0 |
What does Oncternal Therapeutics, Inc. do?
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
James B. Breitmeyer insider trading
Oncternal Therapeutics key executives
Oncternal Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Gunnar F. Kaufmann Ph.D. (49) Chief Scientific Officer
- Dr. James B. Breitmeyer (71) Pres, Chief Executive Officer & Director